2020 American Society of Hematology Virtual Annual Meeting*

Download All
December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Review slidesets and expert analyses of key data from the 2020 Hematology Virtual Annual Meeting!
Hanny Al-Samkari, MD
John M. Burke, MD
Jorge Cortes, MD
Amy E. DeZern, MD, MHS
Shaji Kumar, MD
Sagar Lonial, MD
Mark A. Schroeder, MD
Jeff P. Sharman, MD
Sujit Sheth, MD
Srdan Verstovsek, MD, PhD
Eunice S. Wang, MD

ClinicalThought

Review experts' perspectives on the most clinically relevant data on malignant and nonmalignant hematology results to be presented at the ASH 2020 annual meeting, including key insights and the latest data you need to understand and integrate into your practice.

Hanny Al-Samkari, MD John M. Burke, MD Jorge Cortes, MD Amy E. DeZern, MD, MHS Shaji Kumar, MD Sagar Lonial, MD Mark A. Schroeder, MD Jeff P. Sharman, MD Sujit Sheth, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Released: December 2, 2020

Acute and Chronic Leukemias

Slidesets Phase III QUAZAR AML-001: Analyses of CC-486 (Oral Azacitidine) vs Placebo as Maintenance Therapy in AML After CR/CRi
Slidesets Phase I Study of Gilteritinib Combined With Induction/Consolidation Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia: Final Results
Slidesets Phase Ib Efficacy, Safety of Anti-CD47 Antibody Magrolimab + Azacitidine in Untreated AML
Slidesets Phase I/II Trial of Flotetuzumab as Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia
Slidesets Phase II Study of Hyper-CVAD + Blinatumomab in Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell ALL
Slidesets Randomized Phase II OPTIC Trial of 3 Starting Doses of Ponatinib in Patients With CP-CML: Analysis by Mutation Status and Line of Therapy
Slidesets Ponatinib After Progression on Second-Generation TKI Therapy in Chronic-Phase Chronic Myeloid Leukemia: Combined Analysis of PACE and OPTIC
Slidesets Updated Analysis of Phase I Trial of Asciminib, a First-in-Class STAMP Inhibitor, in Patients With Previously Treated BCR-ABL1 T315I–Mutated CML
Slidesets QUAZAR AML-001 Phase III Trial of Oral AZA (CC-486) vs Placebo as Maintenance Therapy in AML After First Remission: Analyses by MRD Status
Slidesets ASCEMBL: Phase III Study of STAMP Inhibitor Asciminib vs Bosutinib for CML-CP Previously Treated With ≥ 2 TKIs

Lymphomas and Chronic Lymphocytic Leukemia

Slidesets TRANSCEND NHL 001: R/R MCL Cohort of Phase I Study of Lisocabtagene Maraleucel
Slidesets CAPTIVATE: Updated Results From the Phase II Trial of First-line Ibrutinib Plus Venetoclax for CLL/SLL
Slidesets MURANO 5-Yr Analysis: Fixed-Duration Venetoclax + Rituximab vs Bendamustine + Rituximab in R/R CLL
Slidesets Phase Ib ACE-CL-003: Acalabrutinib Combined With Venetoclax and Obinutuzumab or Rituximab in Treatment-Naive or Relapsed/Refractory CLL
Slidesets Predictors of Response to Third-Line Tazemetostat in Relapsed/Refractory Follicular Lymphoma
Slidesets UNITY-NHL: Umbralisib Monotherapy in Patients With R/R Indolent NHL
Slidesets Pooled Analysis of Cardiovascular Events From Clinical Trials Evaluating Acalabrutinib Monotherapy in CLL
Slidesets CITADEL-204 Phase II Trial of Parsaclisib, a PI3Kδ Inhibitor, in Relapsed/Refractory Marginal Zone Lymphoma
Slidesets Phase I Study of Odronextamab, a Novel Bispecific Antibody Targeting CD3 and CD20, for Patients With Heavily Pretreated B-Cell NHL
Slidesets SGN35-015: Phase II Study of Frontline Brentuximab Vedotin ± Second Agent for Older Patients With cHL Ineligible for Standard CT
Slidesets Phase I/II BRUIN Trial of LOXO-305 in Previously Treated Patients With CLL/SLL
Slidesets UNITY-CLL: Phase III Trial of Umbralisib + Ublituximab vs Obinutuzumab + Chlorambucil in Patients With CLL
Slidesets TRANSCEND CLL 004: Phase I Results With Lisocabtagene Maraleucel + Ibrutinib in Relapsed/Refractory CLL/SLL
Slidesets ZUMA-5: Phase II Study of Axicabtagene Ciloleucel in R/R Indolent Non-Hodgkin Lymphoma
Slidesets Phase I Trial of Mosunetuzumab Bispecific Antibody in Multiply Relapsed Follicular Lymphoma

Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Slidesets Oral Roxadustat in Anemia Secondary to Lower-Risk MDS: 1-Yr Analysis
Slidesets Phase II Study of Luspatercept in RBC Transfusion-Dependent Patients With Myelofibrosis-Associated Anemia: Updated Results
Slidesets CONTINUATION-PV: 5-Yr Results of Ropeginterferon α-2b in Polycythemia Vera
Slidesets Correlation of Survival and Other Clinical Benefits With Imetelstat Therapy in High-Risk, JAK Inhibitor–Refractory Myelofibrosis
Slidesets MANIFEST: Novel BET Inhibitor, CPI-0610, Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis Patients
Slidesets Randomized Phase II Study of Pevonedistat Plus Azacitidine vs Azacitidine: Post Hoc Analysis in Higher-Risk MDS
Slidesets DACOTA Phase III Study of Decitabine vs Hydroxyurea for Advanced Proliferative CMML
Slidesets BMT CTN 1102: RIC Allogeneic HSCT vs Non-HSCT Therapy in Patients 50-75 Yrs With Higher-risk MDS

Multiple Myeloma

Slidesets First-in-Human Phase I UNIVERSAL Trial of Allogeneic CAR T-Cell Therapy With ALLO-715 (Anti-BCMA) and ALLO-647 (Anti-CD52) in Patients With R/R MM
Slidesets Updated Analysis of Phase I CRB-402: bb21217 Anti-BCMA CAR T-Cell Therapy in Patients With R/R MM
Slidesets PRIME Phase I/II Trial of P-BCMA-101: Novel CAR T-Cell Therapy in R/R Multiple Myeloma
Slidesets Phase II DREAMM-2 Study of Belantamab Mafodotin in R/R MM: Outcomes by Number of Prior Therapies
Slidesets Phase II DREAMM-6 Arm B: Preliminary Analysis of Belantamab Mafodotin + Bortezomib/Dexamethasone in R/R MM
Slidesets DREAMM-2: Ocular Safety During Phase II Study of Belantamab Mafodotin in R/R MM
Slidesets CARTITUDE-1 Phase Ib/II Study of Ciltacabtagene Autoleucel: BCMA-Directed CAR T-Cell Therapy in Patients With R/R MM
Slidesets BCMA-Targeted ADC MEDI2228: First-in-Human Phase I Study in Patients With R/R Multiple Myeloma
Slidesets Phase I Trial: Updated Analysis of BCMA x CD3 Bispecific Antibody Teclistamab (JNJ-64007957) in Patients With R/R MM
Slidesets First-in-Human Phase I Study of AMG 701: Anti-BCMA Bispecific Antibody in Patients With R/R MM
Slidesets MAIA Updated Analysis: Phase III Study of D-Rd vs Rd for ASCT-Ineligible Newly Diagnosed MM
Slidesets First-in-Human Phase I Trial of GPCR5D x CD3 Bispecific Antibody Talquetamab in Patients With R/R MM
Slidesets First-in-Human Phase I Study of BCMA x CD3 Bispecific Antibody REGN5458 in Patients With R/R MM
Slidesets Cevostamab: Novel FcRH5 x CD3 Bispecific Antibody in Patients With R/R MM
Slidesets Phase III APOLLO: Daratumumab SC + Pom/Dex vs Pom/Dex Alone in Patients With R/R MM
Slidesets GRIFFIN Maintenance Phase Update: Daratumumab + VRd → Dara-R vs VRd → R Alone for ASCT-Eligible Patients With Newly Diagnosed MM
Slidesets TOURMALINE-MM2: Oral Ixazomib-Rd vs Placebo-Rd for ASCT-Ineligible Patients With Newly Diagnosed MM
Slidesets Phase I/II Trial of Iberdomide Plus Daratumumab/Dex or Bortezomib/Dex in R/R MM
Slidesets ALGONQUIN Part 1: Phase I Trial of Belantamab Mafodotin With Pomalidomide/Dexamethasone in Patients With R/R Multiple Myeloma
Slidesets STOMP Phase I/II Trial: Selinexor/Pomalidomide/Dexamethasone in R/R MM After ≥ 2 Previous Therapies

Nonmalignant Hematology

Slidesets Phase I/II Trial of BTK Inhibitor Rilzabrutinib (PRN1008) for Heavily Pretreated Patients With Immune Thrombocytopenia
Slidesets ROCKstar Phase II Trial of Daily or Twice-Daily Belumosudil (KD025) in Previously Treated Patients With Chronic GVHD
Slidesets GRAVITAS-119: Phase I Study of Itacitinib Plus Calcineurin Inhibitors as Prophylaxis for GVHD
Slidesets Phase I/II Study of JAK1/2 Inhibitor Baricitinib in Refractory Chronic GVHD
Slidesets BELIEVE: HRQoL Outcomes for Patients With Transfusion-Dependent β-Thalassemia Treated With Luspatercept
Slidesets CLIMB THAL-111/SCD-121: Phase I/II Studies of CTX001 for Transfusion-Dependent β-Thalassemia and Sickle Cell Disease
Slidesets Phase I Dose-Escalation Study of Mitapivat (AG-348) in Patients With Sickle Cell Disease
Slidesets REACH3: Phase III Trial of Ruxolitinib vs Best Available Therapy in Steroid-Refractory/Dependent, Chronic GVHD
Slidesets FLIGHT: First-line Mycophenolate + Steroids vs Standard Steroid Treatment in Patients With Newly Diagnosed Immune Thrombocytopenia Purpura
Slidesets Phase III HOPE-B: Etranacogene Dezaparvovec Gene Therapy in Adults With Severe or Moderately Severe Hemophilia B
Provided by Clinical Care Options, LLC
Contact Info

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue